MXPA98003802A - Preparaciones de hormona tiroidea estabilizadas ymetodos para fabricar las mismas. - Google Patents

Preparaciones de hormona tiroidea estabilizadas ymetodos para fabricar las mismas.

Info

Publication number
MXPA98003802A
MXPA98003802A MXPA98003802A MX9803802A MXPA98003802A MX PA98003802 A MXPA98003802 A MX PA98003802A MX PA98003802 A MXPA98003802 A MX PA98003802A MX 9803802 A MX9803802 A MX 9803802A MX PA98003802 A MXPA98003802 A MX PA98003802A
Authority
MX
Mexico
Prior art keywords
preparations
thyroid hormone
disclosed
methods
making same
Prior art date
Application number
MXPA98003802A
Other languages
English (en)
Spanish (es)
Inventor
L Thomas Charles Iii
Original Assignee
Abbott Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Gmbh & Co Kg filed Critical Abbott Gmbh & Co Kg
Publication of MXPA98003802A publication Critical patent/MXPA98003802A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MXPA98003802A 1995-11-14 1996-11-14 Preparaciones de hormona tiroidea estabilizadas ymetodos para fabricar las mismas. MXPA98003802A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US673895P 1995-11-14 1995-11-14
US1731496P 1996-05-13 1996-05-13
PCT/IB1996/001330 WO1997017951A1 (en) 1995-11-14 1996-11-14 Stabilized thyroid hormone preparations and methods of making same

Publications (1)

Publication Number Publication Date
MXPA98003802A true MXPA98003802A (es) 2005-04-29

Family

ID=26675995

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA98003802A MXPA98003802A (es) 1995-11-14 1996-11-14 Preparaciones de hormona tiroidea estabilizadas ymetodos para fabricar las mismas.

Country Status (12)

Country Link
US (2) US5955105A (cg-RX-API-DMAC10.html)
EP (1) EP0861073B1 (cg-RX-API-DMAC10.html)
JP (1) JP2000500155A (cg-RX-API-DMAC10.html)
AT (1) ATE271863T1 (cg-RX-API-DMAC10.html)
AU (1) AU712217B2 (cg-RX-API-DMAC10.html)
BR (1) BR9611306A (cg-RX-API-DMAC10.html)
CA (1) CA2235707A1 (cg-RX-API-DMAC10.html)
DE (1) DE69633018T2 (cg-RX-API-DMAC10.html)
ES (1) ES2224184T3 (cg-RX-API-DMAC10.html)
MX (1) MXPA98003802A (cg-RX-API-DMAC10.html)
PT (1) PT861073E (cg-RX-API-DMAC10.html)
WO (1) WO1997017951A1 (cg-RX-API-DMAC10.html)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19821625C1 (de) * 1998-05-15 2000-01-05 Merck Patent Gmbh Pharmazeutische Zubereitung
DE19830246A1 (de) * 1998-07-07 2000-01-13 Merck Patent Gmbh Pharmazeutische Zubereitung
AU3699000A (en) * 1999-03-10 2000-09-28 Lotus Biochemical Corporation Use of protein conformation for the protection and release of chemical compounds
US6716452B1 (en) * 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
EP1207852A4 (en) * 1999-09-02 2009-11-11 Nostrum Pharmaceuticals Inc ORAL PHARMACEUTICALS WITH TAXED RELEASE FOR ORAL ADMINISTRATION
US6627660B1 (en) 1999-11-16 2003-09-30 New River Pharmaceuticals Inc. Stabilized thyroxine compounds
US20070141107A1 (en) * 2000-03-15 2007-06-21 Orbusneich Medical, Inc. Progenitor Endothelial Cell Capturing with a Drug Eluting Implantable Medical Device
US9522217B2 (en) 2000-03-15 2016-12-20 Orbusneich Medical, Inc. Medical device with coating for capturing genetically-altered cells and methods for using same
US8088060B2 (en) 2000-03-15 2012-01-03 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
US6399101B1 (en) * 2000-03-30 2002-06-04 Mova Pharmaceutical Corp. Stable thyroid hormone preparations and method of making same
DK1300160T3 (da) 2000-05-24 2014-03-24 Otsuka Pharma Co Ltd Fremgangsmåde til stabilisering af en sammensætning
EP1157682A1 (en) * 2000-05-25 2001-11-28 Cilag AG Blister package for topiramate tablets
US6979462B1 (en) 2000-10-03 2005-12-27 Mutual Pharmaceutical Co., Inc. Stabilization of solid drug formulations
US6855333B1 (en) * 2000-10-03 2005-02-15 Mutual Pharmaceutical Co., Inc. Stabilization of solid thyroid drug formulations
US8394813B2 (en) 2000-11-14 2013-03-12 Shire Llc Active agent delivery systems and methods for protecting and administering active agents
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
SI1413331T1 (sl) 2001-01-26 2008-02-29 Schering Corp Kombinacije fenofibrata peroksisomskega proliferator aktivirajocega receptorja (PPAR) z ezetimib zaviralcem absorpcije sterola za vaskularne indikacije
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
RS50406B (sr) 2001-01-26 2009-12-31 Schering Corporation, Upotreba supstituisanih jedinjenja azetidinona za lečenje sitosterolemije
EP1365745A2 (en) * 2001-02-15 2003-12-03 King Pharmaceuticals, Inc. Stabilized pharmaceutical and thyroid hormone compositions and method of preparation
US6555581B1 (en) 2001-02-15 2003-04-29 Jones Pharma, Inc. Levothyroxine compositions and methods
US20030224047A1 (en) * 2001-02-15 2003-12-04 Franz G. Andrew Levothyroxine compositions and methods
US20030032675A1 (en) * 2001-02-15 2003-02-13 Franz G. Andrew Manufacture of thyroid hormone tablets having consistent active moiety amounts
GB0113841D0 (en) * 2001-06-07 2001-08-01 Boots Co Plc Therapeutic agents
ITMI20011401A1 (it) * 2001-07-02 2003-01-02 Altergon Sa Formulazioni farmaceutiche per ormoni tiroidei
US20030198667A1 (en) * 2001-08-10 2003-10-23 Franz Andrew G. Methods of producing dispersible pharmaceutical compositions
US20030199585A1 (en) * 2001-08-10 2003-10-23 Franz G Andrew Levothyroxine compositions and methods
US20030180353A1 (en) * 2001-08-10 2003-09-25 Franz G. Andrew Stabilized pharmaceutical compositions
US20030194436A1 (en) * 2001-08-10 2003-10-16 Franz Andrew G. Immediate release pharmaceutical compositions
US20030190349A1 (en) * 2001-08-10 2003-10-09 Franz G. Andrew Methods of stabilizing pharmaceutical compositions
US20030198671A1 (en) * 2001-08-10 2003-10-23 Franz G. Andrew Levothyroxine compositions having unique plasma AUC properties
AU2002332507A1 (en) * 2001-08-10 2003-02-24 King Pharmaceuticals, Inc. Levothyroxine compositions and methods
US20030195253A1 (en) * 2001-08-14 2003-10-16 Franz G. Andrew Unadsorbed levothyroxine pharmaceutical compositions, methods of making and methods of administration
US7101569B2 (en) 2001-08-14 2006-09-05 Franz G Andrew Methods of administering levothyroxine pharmaceutical compositions
US20030199587A1 (en) * 2001-08-14 2003-10-23 Franz G. Andrew Levothyroxine compositions having unique Cmax properties
US20030194437A1 (en) * 2001-08-14 2003-10-16 Franz G. Andrew Levothyroxine compositions having unique triiodothyronine Cmax properties
US20030199586A1 (en) * 2001-08-14 2003-10-23 Franz G. Andrew Unique levothyroxine aqueous materials
US20030203967A1 (en) * 2001-08-14 2003-10-30 Franz G. Andrew Levothyroxine compositions having unique Tmax properties
AU2002341555A1 (en) * 2001-08-14 2003-09-02 King Pharmaceuticals, Inc. Levothyroxine pharmaceutical compositions, methods of making and methods of administration
US20030198672A1 (en) * 2001-08-14 2003-10-23 Franz G. Andrew Levothyroxine compositions having unique triidothyronine plasma AUC properties
US20060014697A1 (en) 2001-08-22 2006-01-19 Travis Mickle Pharmaceutical compositions for prevention of overdose or abuse
US7169752B2 (en) 2003-09-30 2007-01-30 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
MXPA04002573A (es) 2001-09-21 2004-06-18 Schering Corp Tratamiento de xantoma con derivados de azetidinona como inhibidores de la absorcion de esterol.
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US20030190359A1 (en) * 2001-10-29 2003-10-09 Franz G. Andrew Levothyroxine compositions having unique triiodothyronine Tmax properties
US6645526B2 (en) 2001-11-13 2003-11-11 Mylan Pharmaceuticals, Inc. Storage stable thyroxine active drug formulations and methods for their production
US20030099699A1 (en) 2001-11-13 2003-05-29 Hanshew Dwight D. Storage stable thyroxine active drug formulations and methods for their production
CA2472690A1 (en) * 2002-01-07 2003-07-17 Abbott Gmbh & Co. Kg Crystallization of amino acids using ultrasonic agitation
AU2003241537A1 (en) * 2002-05-23 2003-12-12 Andrx Corporation Biguanide formulations
WO2004014318A2 (en) * 2002-08-10 2004-02-19 King Pharmaceuticals, Inc. Levothyroxine compositions and methods
US20040152783A1 (en) * 2002-11-05 2004-08-05 Olon Lawrence Peter Controlled absorption of admixed thyroid hormone formulations
EP1562582A1 (en) 2002-11-06 2005-08-17 Schering Corporation Cholesterol absorption inhibitors for the treatment of demyelination
ITMI20110713A1 (it) 2011-04-29 2012-10-30 Bracco Imaging Spa Processo per la preparazione di un derivato solfatato di3,5-diiodo-o-[3-iodofenil]-l-tirosina
ITMI20022394A1 (it) 2002-11-13 2004-05-14 Bracco Spa Uso di triiodotironina 3-solfato come farmaco ad attivita' tireomimetica e relative formulazioni farmaceutiche.
ES2311806T3 (es) 2003-03-07 2009-02-16 Schering Corporation Compuesto de azetidinona sustituidos, fornulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
US7192944B2 (en) * 2003-03-07 2007-03-20 Schering Corp. Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
JP4589919B2 (ja) 2003-03-07 2010-12-01 シェーリング コーポレイション 高コレステロール血症の処置のための、置換アゼチジノン化合物、これらの処方物および使用
WO2004096177A1 (de) 2003-05-02 2004-11-11 Globopharm Pharmazeutische Produktions- Und Handelsgesellschaft M.B.H. Feste pharmazeutische zubereitung enthaltend levothyroxin- und/oder liothyroninsalze
US8293272B2 (en) * 2003-05-02 2012-10-23 Globopharm Pharmazeutische Produktions-Und Handelsgesellschaft M.B.H. Solid pharmaceutical preparation containing levothyroxine and/or liothyronine salts
GB0316206D0 (en) * 2003-07-10 2003-08-13 Glaxo Group Ltd Pharmaceutical formulation
US20060008512A1 (en) * 2004-07-07 2006-01-12 Hooge Danny M Composition and methods for improved animal performance
JP5173832B2 (ja) * 2006-01-06 2013-04-03 インターベツト・インターナシヨナル・ベー・ベー 濃縮液体甲状腺ホルモン組成物
US7858663B1 (en) 2007-10-31 2010-12-28 Pisgah Laboratories, Inc. Physical and chemical properties of thyroid hormone organic acid addition salts
GB2457710A (en) * 2008-02-25 2009-08-26 Andrew Nicolaou Thyroxine and its use in weight loss and obesity treatment
IT1395454B1 (it) * 2009-03-24 2012-09-21 Altergon Sa Composizioni e forme farmaceutiche per somministrazione orale di ormoni tiroidei in grado di contrastare l'azione di agenti sequestranti nel tratto gastrointestinale
EP2248518B1 (en) 2009-04-17 2013-01-16 Merz Pharma GmbH & Co. KGaA Formulation for stabilizing proteins, peptides or mixtures thereof.
EP2461804A4 (en) * 2009-08-04 2013-10-02 Haren Treasurer IMPROVED USE WITH THYROID HORMONE
AU2011316111B2 (en) 2010-10-12 2015-05-28 Merz Pharma Gmbh & Co. Kgaa Formulation suitable for stabilizing proteins, which is free of mammalian excipients
AR083417A1 (es) 2010-10-14 2013-02-21 Novartis Ag Composiciones farmaceuticas que contienen un dgat1 inhibidor
ES2645295T3 (es) * 2011-04-08 2017-12-04 Bracco Imaging S.P.A Proceso para la preparación de un derivado sulfatado de 3,5-diyodo-O-[3-yodofenil]-L-tirosina
WO2013033194A1 (en) 2011-08-30 2013-03-07 Fresenius Kabi Usa, Llc Levothyroxine formulations
US8779000B1 (en) * 2013-07-20 2014-07-15 Nilesh Parikh Saccharide free, storage stable thyroid hormone active drug formulations and methods for their production
EP2932963A1 (en) * 2014-04-16 2015-10-21 Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. Stable pharmaceutical dosage forms comprising Levothyroxine sodium
WO2017013591A1 (en) 2015-07-22 2017-01-26 Leiutis Pharmaceuticals Pvt Ltd Stabilized liquid formulation of levothyroxine
DE112016005058T5 (de) 2015-11-04 2018-07-19 Leiutis Pharmaceuticals Pvt Ltd Neue Levothyroxin-Formulierungen zur oralen Anwendung
NL2017110B1 (en) * 2016-07-05 2018-01-12 Emp Levo Gmbh Methods for the preparation of a levothyroxine solution
US10231931B1 (en) 2018-03-23 2019-03-19 Genus Lifesciences Inc. Thyroid hormone oral dosage forms and methods of using the same
TW202227047A (zh) * 2020-10-09 2022-07-16 日商Ａｓｋａ製藥股份有限公司 甲狀腺荷爾蒙的製劑化方法
WO2023088976A1 (en) 2021-11-16 2023-05-25 Tap Pharmaceuticals, Ag Orodispersible levothyroxine compositions

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4369172A (en) * 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
CH658188A5 (de) * 1984-03-23 1986-10-31 Ciba Geigy Ag Lagerstabile schnellzerfallende pharmazeutische presslinge.
US4851228A (en) * 1984-06-20 1989-07-25 Merck & Co., Inc. Multiparticulate controlled porosity osmotic
US4786503A (en) * 1987-04-06 1988-11-22 Alza Corporation Dosage form comprising parallel lamine
US5102666A (en) * 1990-09-11 1992-04-07 Oramed, Inc. Calcium polycarbophil controlled release composition and method
US5275820A (en) * 1990-12-27 1994-01-04 Allergan, Inc. Stable suspension formulations of bioerodible polymer matrix microparticles incorporating drug loaded ion exchange resin particles
US5225204A (en) * 1991-11-05 1993-07-06 Chen Jivn Ren Stable dosage of levothyroxine sodium and process of production
ES2115638T3 (es) * 1991-12-30 1998-07-01 Akzo Nobel Nv Composicion tiroactiva de liberacion controlada.
DE4318577A1 (de) * 1993-06-04 1994-12-08 Merck Patent Gmbh Schmiermittelfreie, arzneimittelhaltige Tabletten
GB9401879D0 (en) * 1994-02-01 1994-03-30 Boots Co Plc Therapeutic agents
GB9401892D0 (en) * 1994-02-01 1994-03-30 Boots Co Plc Therapeutic agents
HUT75956A (en) * 1995-11-29 1997-05-28 Cyclolab Pharmaceutical composition containing thyroxine

Also Published As

Publication number Publication date
DE69633018T2 (de) 2004-12-09
EP0861073B1 (en) 2004-07-28
AU712217B2 (en) 1999-11-04
AU7584996A (en) 1997-06-05
ATE271863T1 (de) 2004-08-15
WO1997017951A1 (en) 1997-05-22
EP0861073A1 (en) 1998-09-02
BR9611306A (pt) 1999-12-28
CA2235707A1 (en) 1997-05-22
US6056975A (en) 2000-05-02
DE69633018D1 (de) 2004-09-02
PT861073E (pt) 2004-10-29
JP2000500155A (ja) 2000-01-11
ES2224184T3 (es) 2005-03-01
US5955105A (en) 1999-09-21

Similar Documents

Publication Publication Date Title
MXPA98003802A (es) Preparaciones de hormona tiroidea estabilizadas ymetodos para fabricar las mismas.
AU7038587A (en) Amino acid chelated compositions
BG101781A (bg) Твърд препарат, съдържащ активно вещество
IE882671L (en) Stabilised human protein formulation
CA2086343A1 (en) Sustained release thyroactive composition
EP0783299A4 (en) COMPOUNDS AND COMPOSITIONS FOR THE ADMINISTRATION OF ACTIVE SUBSTANCES
EP0787497A3 (en) Pharmaceutical preparation containing human growth hormone
HUP9802287A2 (hu) Cinkkel és kívánt esetben lizinnel vagy kalciumionnal előkezelt növekedési hormont tartalmazó stabilizált gyógyszerkészítmény
CA2033725A1 (en) Pharmaceutical and cosmetic compositions containing a salt of cholanic acid
IE842579L (en) Cimetidine containing compositions
AU3394689A (en) Pharmaceutical compositions
EP0208519A3 (en) Solubilized composition of hardly-soluble pharmaceutical product
TW372193B (en) Novel pharmaceutical composition for the preparation of a stable powder containing an association of acetylsalicylic acid and metoclopramide as the active ingredient
AU566228B2 (en) Compressed hydroxybutryic acid polymer retarded release vehicle
JPS6416724A (en) Stable and injectable vinca dimer salt solution
NZ331083A (en) Pharmaceutical preparations of cilansetron stabilized against racemization
EP0397147A3 (en) Stable solutions of rebeccamycin analog and preparation thereof
MX9500130A (es) Preparaciones orales en semi-pasta.
AU629445B2 (en) Improvements in or relating to topical compositions containing 1 alpha 25-dihydroxycholecalciferol
IL127851A0 (en) Inhibition of TNF activity
GB2258397A (en) Pharmaceutical compositions containing amethocaine
BG103412A (en) Stabilized pharmaceutical compositions based on chinupristine and dalfopristine and their preparation
JPS6416728A (en) Aqueous preparation
JPS57200361A (en) "indomethacin(r)" pharmaceutical with low irritant action
EP0063328A3 (en) Compositions containing secretin and method for preventing the adsorption of secretin

Legal Events

Date Code Title Description
GB Transfer or rights